Patents by Inventor Antonio Ricci

Antonio Ricci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220135571
    Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: December 21, 2021
    Publication date: May 5, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, Annick Goergler, Georg Jaeschke, Bernd Kuhn, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner, David Hewings, Yvonne Alice Nagel
  • Publication number: 20220127275
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Application
    Filed: January 4, 2022
    Publication date: April 28, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara BIEMANS, Georg JAESCHKE, Antonio RICCI, Daniel RUEHER, Fionn O'HARA
  • Publication number: 20220112199
    Abstract: The invention provides novel a compound having the general formula (I) as described herein, compositions including the compound and methods of using the compound.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: Cosimo Dolente, Annick Goergler, David Hewings, Georg Jaeschke, Bernd Kuhn, Yvonne Alice Nagel, Roger David Norcross, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • Publication number: 20220041680
    Abstract: The present invention provides a process for the manufacture of GLP-1 analogues with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a C-terminal pseudoproline fragment A with a fragment B bound to a solid support, followed by deprotection and cleavage from the support and final purification to yield the desired peptide. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: October 9, 2019
    Publication date: February 10, 2022
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Giuseppina Maria INCISIVO, Andrea ORLANDIN, Antonio RICCI, Ivan GURYANOV, Walter CABRI
  • Patent number: 11242349
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Georg Jaeschke, Antonio Ricci, Daniel Rueher, Fionn O'Hara
  • Publication number: 20220033443
    Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 3, 2022
    Applicant: Fresenius Kabi iPSUM S.r.l
    Inventors: Antonio RICCI, Jacopo ZANON, Walter CABRI, Ivan GURYANOV, Andrea ORLANDIN, Barbara BIONDI, Fernando FORMAGGIO, Dario VISENTINI
  • Patent number: 11168114
    Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: November 9, 2021
    Assignee: FRESENIUS KABI IPSUM S.R.L
    Inventors: Antonio Ricci, Jacopo Zanon, Walter Cabri, Ivan Guryanov, Andrea Orlandin, Barbara Biondi, Fernando Formaggio, Dario Visentini
  • Publication number: 20210300844
    Abstract: The present invention relates to ethynyl derivatives of formula I with variables as defined herein, or to a pharmaceutically acceptable acid addition salt thereof Compounds of formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).
    Type: Application
    Filed: June 3, 2021
    Publication date: September 30, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Jaeschke, Lothar Lindemann, Antonio Ricci, Eric Vieira
  • Patent number: 11117890
    Abstract: The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, generally of Formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: September 14, 2021
    Assignee: Hoffman La-Roche Inc.
    Inventors: Georg Jaeschke, Antonio Ricci, Daniel Rueher, Sandra Steiner, Martin Duplessis, Yvonne Alice Nagel, Bernd Kuhn
  • Publication number: 20210269452
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: May 9, 2021
    Publication date: September 2, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Publication number: 20210238230
    Abstract: The present invention provides a process for the manufacture of peptidomimetic drug icatibant with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a protected C-terminal fragment bound to a solid support and a protected N-terminal fragment, followed by cleavage from the support and resulting in a crude peptide of high purity, which is further purified to obtain pure icatibant in high yield. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 5, 2021
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Walter CABRI, Alice POZZEBON, Angelo VIOLA, Antonio RICCI, Andrea BORGOGNO, Ivan GURYANOV
  • Patent number: 11059766
    Abstract: The present invention relates to ethynyl derivatives of formula I with variables as defined herein, or to a pharmaceutically acceptable acid addition salt thereof. Compounds of formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: July 13, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Georg Jaeschke, Lothar Lindemann, Antonio Ricci, Eric Vieira
  • Patent number: 11034699
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: June 15, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Publication number: 20210079005
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Application
    Filed: November 25, 2020
    Publication date: March 18, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Martin Duplessis, Annick Goergler, Georg Jaeschke, Buelent Kocer, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Ulrike Obst Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • Publication number: 20210070739
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Application
    Filed: November 24, 2020
    Publication date: March 11, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • Patent number: 10882848
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: January 5, 2021
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • Publication number: 20200399339
    Abstract: The present invention provides an improved process for the preparation of high purity glucagon comprising the use of Xmb-protected amino acids, wherein may Xmb include, e.g., 2,4,6-trimethoxybenzyl, 2,4-dimethoxybenzyl, or 2-hydroxy-4-methoxybenzyl. The process also comprises the use of building blocks such as pseudoprolines to avoid aggregation and obtain the product in high yield and purity.
    Type: Application
    Filed: June 18, 2020
    Publication date: December 24, 2020
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Andrea ORLANDIN, Antonio RICCI, Walter CABRI, Steve MCINTYRE, Alex SAUNDERS
  • Publication number: 20200361930
    Abstract: The present invention provides compounds that cause specifically the degradation of EGFR via the targeted ubiquitination of EGFR protein and subsequent proteasomal degradation. The present compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: August 4, 2020
    Publication date: November 19, 2020
    Applicants: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.
    Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • Publication number: 20200308171
    Abstract: Present invention provides bifunctional compounds that comprise an E3 Ubiquitin Ligase moiety that is linked to a moiety that inhibit EGFR, where the target protein can be proximate to the ubiquitin ligase to effect degradation of said protein. Present compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Applicants: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.
    Inventors: Georg Jaeschke, Bernd Kuhn, Antonio Ricci, Daniel Rueher, Sandra Steiner, Yvonne Alice Nagel, Martin Duplessis, Kiel Lazarski, Yanke Liang
  • Publication number: 20200255440
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara BIEMANS, Georg JAESCHKE, Antonio RICCI, Daniel RUEHER, Fionn O'HARA